Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

2026-06-13 · Source: The AI Journal · Field: Finance & Economics — Capital Markets & Investment Management, Life Sciences Investment · Depth: Fundamental Awareness, short

Summary

Kos Biotechnology Partners, a global life sciences investment firm based in New York and Athens, Greece, announced the third closing of its inaugural global life sciences fund, securing \$123M (€106M) in total capital commitments. Launched in December 2025, the fund is backed by institutional investors, including lead investor Hellenic Development Bank of Investments (HDBI), and global family offices. This fund marks the first life sciences-dedicated investment fund in Greece, the largest venture capital fund launch in Greece's history, and one of Europe's largest first-time life sciences VC launches. Kos deploys capital flexibly across all development stages, targeting high-impact investments in biotech/novel therapeutics, pharma services, and tech-enabled technologies. The firm has already completed two investments, including leading a financing round for Epikast.

Key takeaway

For entrepreneurs in the life sciences sector seeking early-stage to Series C funding, Kos Biotechnology Partners' \$123M fund offers a significant new capital source. If your venture bridges US scientific innovation with Europe's ecosystem, consider their focus on biotech/novel therapeutics, pharma services, and tech-enabled technologies. Note their flexible investment approach and operational partnership model, which provides a strategic opportunity for companies aiming for global scale.

Key insights

Bridging US biopharma expertise with Europe's ecosystem creates significant life sciences investment opportunities.

Principles

• Converging biology, data science, and computing drives disease cures.
• Flexible capital deployment supports all development stages.
• Cross-border theses validate investment potential.

Method

Kos Biotechnology Partners' method involves deploying strategic capital flexibly across all development stages, from company formation through Series C, targeting biotech/novel therapeutics, pharma services, and tech-enabled technologies.

In practice

• Invest in first-in-class novel therapeutics.
• Support next-gen pharma services platforms.
• Capitalize on computational tools for de-risking.

Topics

• Life Sciences Investment
• Venture Capital
• Biotech Therapeutics
• Pharma Services
• Tech-Enabled Health
• Cross-Border Investment

Best for: Investor, Entrepreneur, Tech Journalist

Related on AIssential

• How leftover fish skins landed this founder a billion-dollar exit: ‘My philosophy has always been to have fun’ — Transforming industrial byproducts into high-value medical solutions can yield significant economic success.
• The Week’s 10 Biggest Funding Rounds: AI, Autonomy And Biotech Top The Ranks — Venture capital megarounds persist, with AI and biotech dominating top U.S. startup funding.
• Biotech Has to Change — Biotech faces immense cost and time pressures due to high failure rates in drug development.
• Norway's Sovereign Wealth Fund is Europe's Missing Venture Capitalist — Europe, despite its strong talent and scientific output, faces a significant lack of risk capital at scale, resulting in smaller venture deals and fewer "unicorns" compared to North America, even thou…
• KOMPAS VC closes €160M Fund II for industrial tech startups — KOMPAS VC's €160M Fund II targets industrial tech for productivity, resilience, and decarbonisation in physical industries.
• ‘The next big thing’: Newfund raises €60m to back brain technologies — Brain technologies represent a significant growth opportunity, driven by scientific maturity and advanced tools like AI.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.